169 related articles for article (PubMed ID: 28360191)
21. S100A11 is a potential prognostic marker for clear cell renal cell carcinoma.
Gabril M; Girgis H; Scorilas A; Rotondo F; Wala S; Bjarnason GA; Ding Q; Evans A; Tawedrous E; Pasic M; Finelli A; Al-Haddad S; Yousef GM
Clin Exp Metastasis; 2016 Jan; 33(1):63-71. PubMed ID: 26472670
[TBL] [Abstract][Full Text] [Related]
22. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic miR-663a is associated with cellular function and poor prognosis in renal cell carcinoma.
Zhou L; Pan X; Li Z; Chen P; Quan J; Lin C; Lai Y; Xu J; Xu W; Guan X; Li H; Gui Y; Lai Y
Biomed Pharmacother; 2018 Sep; 105():1155-1163. PubMed ID: 30021352
[TBL] [Abstract][Full Text] [Related]
24. High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.
Wu XR; Sha JJ; Liu DM; Chen YH; Yang GL; Zhang J; Chen YY; Bo JJ; Huang YR
Eur J Surg Oncol; 2013 Jan; 39(1):100-6. PubMed ID: 23102595
[TBL] [Abstract][Full Text] [Related]
25. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
Du P; Ye L; Yang Y; Jiang WG
Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
[TBL] [Abstract][Full Text] [Related]
26. High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma.
Lee C; Park JW; Suh JH; Moon KC
Pathol Res Pract; 2015 Nov; 211(11):824-8. PubMed ID: 26296917
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.
Heinzelmann J; Unrein A; Wickmann U; Baumgart S; Stapf M; Szendroi A; Grimm MO; Gajda MR; Wunderlich H; Junker K
Ann Surg Oncol; 2014 Mar; 21(3):1046-54. PubMed ID: 24242678
[TBL] [Abstract][Full Text] [Related]
28. Profiling microRNA from nephrectomy and biopsy specimens: predictors of progression and survival in clear cell renal cell carcinoma.
Kowalik CG; Palmer DA; Sullivan TB; Teebagy PA; Dugan JM; Libertino JA; Burks EJ; Canes D; Rieger-Christ KM
BJU Int; 2017 Sep; 120(3):428-440. PubMed ID: 28432832
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.
Mytsyk Y; Dosenko V; Borys Y; Kucher A; Gazdikova K; Busselberg D; Caprnda M; Kruzliak P; Farooqi AA; Lubov M
Int Urol Nephrol; 2018 May; 50(5):851-859. PubMed ID: 29549624
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-217, down-regulated in clear cell renal cell carcinoma and associated with lower survival, suppresses cell proliferation and migration.
Li H; Zhao J; Zhang JW; Huang QY; Huang JZ; Chi LS; Tang HJ; Liu GQ; Zhu DJ; Ma WM
Neoplasma; 2013; 60(5):511-5. PubMed ID: 23790169
[TBL] [Abstract][Full Text] [Related]
31. High expression of KCa3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival.
Rabjerg M; Oliván-Viguera A; Hansen LK; Jensen L; Sevelsted-Møller L; Walter S; Jensen BL; Marcussen N; Köhler R
PLoS One; 2015; 10(4):e0122992. PubMed ID: 25848765
[TBL] [Abstract][Full Text] [Related]
32. Decreased expression of mucin 18 is associated with unfavorable postoperative prognosis in patients with clear cell renal cell carcinoma.
Bai Q; Liu L; Long Q; Xia Y; Wang J; Xu J; Guo J
Int J Clin Exp Pathol; 2015; 8(9):11005-14. PubMed ID: 26617818
[TBL] [Abstract][Full Text] [Related]
33. Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival.
Belsante M; Darwish O; Youssef R; Bagrodia A; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
Urol Oncol; 2014 Jan; 32(1):30.e23-8. PubMed ID: 23428539
[TBL] [Abstract][Full Text] [Related]
34. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression.
Chen X; Wang X; Ruan A; Han W; Zhao Y; Lu X; Xiao P; Shi H; Wang R; Chen L; Chen S; Du Q; Yang H; Zhang X
Clin Cancer Res; 2014 May; 20(10):2617-30. PubMed ID: 24647573
[TBL] [Abstract][Full Text] [Related]
35. miR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN/SMAD4 expression.
Ma Q; Peng Z; Wang L; Li Y; Wang K; Zheng J; Liang Z; Liu T
Int J Oncol; 2016 Dec; 49(6):2589-2599. PubMed ID: 27779660
[TBL] [Abstract][Full Text] [Related]
36. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma.
Heinzelmann J; Henning B; Sanjmyatav J; Posorski N; Steiner T; Wunderlich H; Gajda MR; Junker K
World J Urol; 2011 Jun; 29(3):367-73. PubMed ID: 21229250
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-10b Promotes Apoptosis via JNK Pathway in Clear Cell Renal Cell Carcinoma.
Qin J; Zhou J; Teng L; Han Y
Nephron; 2018; 139(2):172-180. PubMed ID: 29672315
[TBL] [Abstract][Full Text] [Related]
38. Human telomerase reverse transcriptase protein expression predicts tumour aggressiveness and survival in patients with clear cell renal cell carcinoma.
Saeednejad Zanjani L; Madjd Z; Abolhasani M; Rasti A; Shariftabrizi A; Mehrazma M; Fodstad Ø; Asgari M
Pathology; 2019 Jan; 51(1):21-31. PubMed ID: 30466948
[TBL] [Abstract][Full Text] [Related]
39. Associations of high expression of miR-106b-5p detected from FFPE sample with poor prognosis of RCC patients.
Liu K; Pan X; Peng X; Zhang C; Li H; Guan X; Xu W; Xu J; Zhao L; Wang T; Lai Y
Pathol Res Pract; 2019 Jun; 215(6):152391. PubMed ID: 31076282
[TBL] [Abstract][Full Text] [Related]
40. A Four-Gene Promoter Methylation Marker Panel Consisting of
van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
